1591 related articles for article (PubMed ID: 17461707)
1. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
2. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia.
Skulas-Ray AC; West SG; Davidson MH; Kris-Etherton PM
Expert Opin Pharmacother; 2008 May; 9(7):1237-48. PubMed ID: 18422480
[TBL] [Abstract][Full Text] [Related]
3. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids.
Bays H
Am J Cardiol; 2006 Aug; 98(4A):71i-76i. PubMed ID: 16919519
[TBL] [Abstract][Full Text] [Related]
4. Omacor (prescription omega-3-acid ethyl esters 90): From severe rhythm disorders to hypertriglyceridemia.
Rupp H
Adv Ther; 2009 Jul; 26(7):675-90. PubMed ID: 19629408
[TBL] [Abstract][Full Text] [Related]
5. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia.
Wohl DA; Tien HC; Busby M; Cunningham C; Macintosh B; Napravnik S; Danan E; Donovan K; Hossenipour M; Simpson RJ
Clin Infect Dis; 2005 Nov; 41(10):1498-504. PubMed ID: 16231263
[TBL] [Abstract][Full Text] [Related]
6. Prescription omega-3-acid ethyl esters for the treatment of very high triglycerides.
Sadovsky R; Kris-Etherton P
Postgrad Med; 2009 Jul; 121(4):145-53. PubMed ID: 19641280
[TBL] [Abstract][Full Text] [Related]
7. Prescription omega-3 fatty acids and their lipid effects: physiologic mechanisms of action and clinical implications.
Bays HE; Tighe AP; Sadovsky R; Davidson MH
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):391-409. PubMed ID: 18327998
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
9. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids.
Rupp H; Wagner D; Rupp T; Schulte LM; Maisch B
Herz; 2004 Nov; 29(7):673-85. PubMed ID: 15580322
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 fatty acids and cardiovascular disease: new developments and applications.
Harris WS; Dayspring TD; Moran TJ
Postgrad Med; 2013 Nov; 125(6):100-13. PubMed ID: 24200766
[TBL] [Abstract][Full Text] [Related]
11. Effect of randomized supplementation with high dose olive, flax or fish oil on serum phospholipid fatty acid levels in adults with attention deficit hyperactivity disorder.
Young GS; Conquer JA; Thomas R
Reprod Nutr Dev; 2005; 45(5):549-58. PubMed ID: 16188207
[TBL] [Abstract][Full Text] [Related]
12. Effect of omega-3 fatty acid supplementation on the arachidonic acid:eicosapentaenoic acid ratio.
Burns T; Maciejewski SR; Hamilton WR; Zheng M; Mooss AN; Hilleman DE
Pharmacotherapy; 2007 May; 27(5):633-8. PubMed ID: 17461697
[TBL] [Abstract][Full Text] [Related]
13. Update on marine omega-3 fatty acids: management of dyslipidemia and current omega-3 treatment options.
Weintraub H
Atherosclerosis; 2013 Oct; 230(2):381-9. PubMed ID: 24075771
[TBL] [Abstract][Full Text] [Related]
14. Docosahexaenoic acid (DHA) and cardiovascular disease risk factors.
Holub BJ
Prostaglandins Leukot Essent Fatty Acids; 2009; 81(2-3):199-204. PubMed ID: 19545988
[TBL] [Abstract][Full Text] [Related]
15. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
Bays HE; Maki KC; Doyle RT; Stein E
Postgrad Med; 2009 Sep; 121(5):145-50. PubMed ID: 19820283
[TBL] [Abstract][Full Text] [Related]
16. Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association.
Skulas-Ray AC; Wilson PWF; Harris WS; Brinton EA; Kris-Etherton PM; Richter CK; Jacobson TA; Engler MB; Miller M; Robinson JG; Blum CB; Rodriguez-Leyva D; de Ferranti SD; Welty FK;
Circulation; 2019 Sep; 140(12):e673-e691. PubMed ID: 31422671
[TBL] [Abstract][Full Text] [Related]
17. Long-term treatment of N-3 PUFAS on plasma lipoprotein levels and fatty acid composition of total serum and erythrocyte lipids in hypertriglyceridemic patients.
Putadechakum S; Tanphaichitr V; Leelahagul P; Pakpeankitvatana V; Surapisitchart T; Komindr S
J Med Assoc Thai; 2005 Feb; 88(2):181-6. PubMed ID: 15962668
[TBL] [Abstract][Full Text] [Related]
18. Clinical overview of algal-docosahexaenoic acid: effects on triglyceride levels and other cardiovascular risk factors.
Ryan AS; Keske MA; Hoffman JP; Nelson EB
Am J Ther; 2009; 16(2):183-92. PubMed ID: 19145206
[TBL] [Abstract][Full Text] [Related]
19. The effect of lean fish consumption on triglyceride levels.
Leaf DA; Hatcher L
Phys Sportsmed; 2009 Apr; 37(1):37-43. PubMed ID: 20048486
[TBL] [Abstract][Full Text] [Related]
20. Effect of fish oil on oxidative stress, lipid profile and renal function in IgA nephropathy.
Parinyasiri U; Ong-Ajyooth L; Parichatikanond P; Ong-Ajyooth S; Liammongkolkul S; Kanyog S
J Med Assoc Thai; 2004 Feb; 87(2):143-9. PubMed ID: 15061297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
